Ads
related to: nexavar side effects sorafenib- Treatment Costs & Savings
See If You Are Eligible For Savings
Or Assistance Programs.
- Helpful Patient Tools
Find Information For Patients Here.
Visit The Official Patient Website.
- Get Treatment Resources
See Tools Specifically For Patients
About Dosing, Savings And More.
- Helpful Resources
Learn About An HIV Treatment
And Discover More About Dosing.
- Important Safety Info
Learn About Possible Side Effects
And View Important Safety Info.
- Talk To Your Doctor
Find Info & Resources To Speak With
Your Doctor About HIV-1 Treatment.
- Treatment Costs & Savings
Search results
Results From The WOW.Com Content Network
Sorafenib, sold under the brand name Nexavar, [3] is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
Sorafenib is a small molecule inhibitor of many tyrosine kinase receptors such as VEGFR-2. Side effects are in most cases mild to moderate such as rash, hand-foot skin reaction, diarrhea and dermatitis, and occur in about 33-38% patients using sorafenib. Other side effects are mild hypertension, leukopenia and bleeding. Uncommon side effects ...
Bayer Healthcare and Onyx Pharmaceuticals announced today that the FDA has bumped up their oral multi-kinase inhibitor Nexavar (sorafenib) tablets assessment to priority review, promising a ...
The most common side effects of Sorafenib include a hand-foot skin reaction and diarrhea. [76] Sorafenib is thought to work by blocking growth of both tumor cells and new blood vessels. Numerous other molecular targeted drugs are being tested as alternative first- and second-line treatments for advanced HCC, such as lenvatinib and regorafenib. [77]
Sunitinib is approved for the treatment of metastatic renal cell carcinoma. Other therapeutic options in this setting are pazopanib (Votrient), sorafenib (Nexavar), temsirolimus (Torisel), interleukin-2 (Proleukin), everolimus (Afinitor), bevacizumab (Avastin), and aldesleukin. Renal cell carcinoma is generally resistant to chemotherapy or ...
Sorafenib, co-developed and co-marketed with Bayer and sold under the trade name Nexavar, is a drug approved in the United States for the treatment of advanced renal cell carcinoma (kidney cancer) in 2005, and for the treatment of inoperable hepatocellular carcinoma, the most common form of liver cancer, in 2007.
Ad
related to: nexavar side effects sorafenib